ArcticZymes Technologies ASA AZT
OSL · Norway · Health Technology
NOK 20.50+0.10 (+0.49%)
Market open· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ArcticZymes Technologies ASA (LTS:0DRV) reports 19% sales growth in Q2 2026, with Molecular Tools surging 84% and EBITDA margin expanding to 23%.
ArcticZymes Technologies ASA (STU:B4V) reports a profitable quarter with a 41% revenue increase and strategic advancements despite regional challenges and currency impacts.
As the European market navigates a complex landscape marked by stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index has remained relatively stable with minor gains. In this environment, identifying stocks that might be trading below their estimated value can present opportunities for investors looking to capitalize on positive earnings momentum despite broader economic challenges.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.